We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Amgen’s Phase III Prolia Study Meets All Endpoints at 12 Months
Amgen’s Phase III Prolia Study Meets All Endpoints at 12 Months
Amgen published positive results from a Phase III trial comparing Prolia (denosumab) with risedronate in patients receiving oral glucocorticoid therapy. The study met all primary and secondary endpoints at 12 months.